Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Response to adjuvant bevacizumab among patients with resected melanoma may vary by age

Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not.

Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma

When oncologists discuss melanoma patients’ options with them following treatment, it’s often not clear whether adjuvant therapy is the best choice.

Cancer Vaccine UV1 Plus Keytruda Shows Safety, Early Efficacy in Advanced Melanoma Trial

Adding UV1, Ultimovacs’ experimental cancer vaccine, to Keytruda (pembrolizumab) is safe and shows initial signs of effectiveness in adults with previously untreated metastatic melanoma, according to top-line data from a Phase 1 clinical trial.

Next generation BRAF inhibitor cancer drug shows promise in early patient trial

A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.